Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment by Tina C Albershardt et al.
POSTER PRESENTATION Open Access
Intratumoral injections of G100 (synthetic TLR4
agonist) increase trafficking of lentiviral vector-
induced antigen-specific CD8 T cells to the tumor
microenvironment
Tina C Albershardt*, Andrea J Parsons, Peter Berglund, Jan ter Meulen
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
The clinical efficacy of tumor-specific effector T cells
can be limited by their proper trafficking to the site of
the tumor and the immunosuppressed local environ-
ment. Strategies to improve homing of effector cells to
tumors and to enhance activity of these effector cells
could further unlock the potential of active cancer
immunotherapy. G100 is the synthetic TLR4 agonist
glucopyranosyl lipid adjuvant (GLA) formulated with an
oil-in-water stable emulsion and has been shown to
induce T cell homing chemokines CXCL9 and CXCL10.
We assessed here whether intratumoral injections of
G100 could improve trafficking of tumor antigen-speci-
fic CD8 T cells to the tumor microenvironment (TME),
thereby achieving better anti-tumor control.
Untreated, B16F10-OVA tumor-bearing mice gener-
ated no detectable levels of ovalbumin (OVA)-specific
CD8 T cell response as assessed by flow cytometry ana-
lysis. In contrast, tumor-bearing mice immunized with
ZVexTM/OVA, a novel lentiviral vector platform expres-
sing OVA, generated 8-9% tumor antigen-specific effec-
tor and memory CD8 T cells within the peripheral
tissue, which remained detectable at low levels even up
to 35 days post-immunization. Tumor-infiltrating lym-
phocytes (TILs) isolated from mice treated with ZVex/
OVA alone had an average of 16.6% antigen-specific
CD8 T cells, whereas those from mice treated with
ZVex/OVA and G100 had 25.9%. While ZVex/OVA-
induced antigen-specific CD8 T cells infiltrated the
tumor without G100, most of these CD8 T cells did not
remain in the TME over time. Intratumoral injections of
G100 not only increased the total number of effector
CD8 T cells within the TME but also kept the CD8
T cells within the TME over time. Furthermore, tumor-
bearing mice treated with ZVex/OVA and G100 had sig-
nificantly improved survival with slower growing
tumors.
We show here that intratumoral injections of a formu-
lated synthetic TLR4 agonist, G100, improved vector-
induced therapeutic efficacy by increasing trafficking of
vector-induced effector T cells toward the TME.
Because G100 also stimulates antigen presentation and
maturation of dendritic cells, intratumoral G100 follow-
ing vector-induced generation of antigen-specific CD8
T cells or adoptive transfer of CAR or TCR T cells may
be an effective way to increase the therapeutic efficacy
of cancer immunotherapy.
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